This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
cancer: Archive
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
ABTPositive Net Change HOLXPositive Net Change QGENPositive Net Change
cancer medical medical-devices
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
REGNNegative Net Change GILDPositive Net Change IBBNegative Net Change XBINegative Net Change SBIONegative Net Change
biotechnology biotechs cancer cell-therapy etfs
Zacks Initiates Coverage of Precipio With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.
PRPOPositive Net Change
cancer medical
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming
NVDANegative Net Change
aerospace alt-energy artificial-intelligence automation biotechnology cancer cloud-computing cybersecurity gene-therapy genomics oncology-screening semiconductor smart-health
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNANegative Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
Top Medical Stocks to Buy for Growth & Performance
by Shaun Pruitt
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
HAENegative Net Change HALONegative Net Change NBIXPositive Net Change
cancer earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
BMYPositive Net Change PFEPositive Net Change BNTXNegative Net Change
cancer oncology-screening
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
JNJPositive Net Change PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology cancer gene-therapy
3 Attractive Medical Stocks to Buy After Earnings
by Shaun Pruitt
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
MCKPositive Net Change EXELPositive Net Change EHCPositive Net Change
biotechnology cancer earnings hospitals investing medical pharmaceuticals
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
NVSNegative Net Change LLYNegative Net Change
artificial-intelligence cancer earnings investing large-cap oncology-screening pharmaceuticals semiconductor tech-stocks
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
NEONegative Net Change NTRAPositive Net Change GHPositive Net Change
cancer genetic-testing genomics oncology-screening smart-health
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
ILMNPositive Net Change
biotechnology cancer genetic-testing genomics oncology-screening smart-health
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
AZNNegative Net Change PFEPositive Net Change MRNANegative Net Change
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth
LNTHNegative Net Change
cancer medical oncology-screening smart-health
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
GSKNegative Net Change NVSNegative Net Change PFEPositive Net Change MRKPositive Net Change AMGNNegative Net Change GILDPositive Net Change VRTXPositive Net Change IBBNegative Net Change SGENPositive Net Change RXDXPositive Net Change XBINegative Net Change SBIONegative Net Change IBBQNegative Net Change
cancer cell-therapy etfs gene-editing
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
NVOPositive Net Change HUMPositive Net Change CHGCYNegative Net Change HZNPPositive Net Change CSLLYNegative Net Change
biotechnology cancer cell-therapy dividend-investing dividends gene-therapy hmo hospitals immuno-therapy insurance large-cap medical pharmaceuticals vaccines
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
by Shaun Pruitt
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
PFEPositive Net Change SGENPositive Net Change
cancer investing medical oncology-screening pharmaceuticals
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Stunning "beat-and-raise" quarter has analysts scrambling to raise estimates and price targets above $110
LNTHNegative Net Change
cancer medical oncology-screening
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
ADAPNegative Net Change KMDAPositive Net Change ZYMEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus immuno-therapy inflation medical
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
GILDPositive Net Change AMGNNegative Net Change MRNANegative Net Change
cancer dividend-investing dividends immuno-therapy medical oncology-screening
How Markets Have Fared Under a Divided Congress
by Bryan Hayes
Markets typically applaud the 'certainty' that comes with a split Congress.
LLYNegative Net Change
cancer dividend-investing dividends earnings immuno-therapy inflation investing large-cap medical oncology-screening pharmaceuticals
Pfizer Earnings Preview: Growth & Diversification is Key
by Shaun Pruitt
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
PFEPositive Net Change JNJPositive Net Change ABBVPositive Net Change
cancer coronavirus dividend-investing dividends earnings hospitals medical oncology-screening pharmaceuticals vaccines
Should Investors Buy Bristol Myers Squibb Stock?
by Shaun Pruitt
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
BMYPositive Net Change PFEPositive Net Change
cancer dividends investing medical oncology-screening
Bull of the Day: Unum Group (UNM)
by Bryan Hayes
Unum Group has consistently enhanced shareholders' value through dividend hikes and share buybacks.
UNMPositive Net Change
cancer dividend-investing dividends earnings finance insurance investing
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
ILMNPositive Net Change NTRAPositive Net Change
biotechnology cancer dna-sequencing genetic-testing genomics oncology-screening smart-health